| Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors (NCT05571969) | Allarity Therapeutics | 2023-03-08 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours (NCT05714553) | NuCana plc | 2023-03-08 |
| Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3 (NCT05715736) | Syneos Health | 2023-03-08 |
| Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (NCT05222932) | TILT Biotherapeutics Ltd. | 2023-03-08 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors (NCT05781360) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2023-03-08 |
| A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects (NCT06905327) | Novartis Pharmaceuticals | 2023-03-08 |
| A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems (NCT05731895) | Boehringer Ingelheim | 2023-03-08 |
| Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine (NCT05691530) | National Institutes of Health Clinical Center (CC) | 2023-03-07 |
| A Study of Etripamil in Healthy Subjects (NCT05511870) | Corxel Pharmaceuticals | 2023-03-07 |
| Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder (NCT05818943) | GRIN Therapeutics, Inc. | 2023-03-07 |
| A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine (NCT06337643) | Matrivax Research and Development Corporation | 2023-03-07 |
| Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets (NCT06180096) | Humanis Saglık Anonim Sirketi | 2023-03-07 |
| Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver (NCT05610826) | University of Chicago | 2023-03-07 |
| Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants (NCT05767398) | BeiGene | 2023-03-07 |
| A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine (NCT05743335) | Immorna Biotherapeutics, Inc. | 2023-03-07 |
| Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (NCT05526924) | University of Chicago | 2023-03-07 |
| Early Goal Nutrition Therapy Guided by Indirect Calorimetry and Nitrogen Balance Among Critically Ill Patients With Acute Kidney Injury (ENGINE Study) (NCT06238674) | Wankawee Jeerangsapasuk | 2023-03-07 |
| A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants (NCT05762276) | Vaxxinity, Inc. | 2023-03-07 |
| Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (NCT05688215) | Jonsson Comprehensive Cancer Center | 2023-03-07 |
| Phase I of XKH001Injection in Healthy Adults (NCT05128409) | Beijing Kanova Biopharmaceutical Co., LTD | 2023-03-07 |
| A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis (NCT05775094) | Memorial Sloan Kettering Cancer Center | 2023-03-07 |
| Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087) | Lapo Alinari | 2023-03-06 |
| A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood (NCT05723874) | Boehringer Ingelheim | 2023-03-06 |
| A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010) (NCT06814106) | Merck Sharp & Dohme LLC | 2023-03-06 |
| Sphenopalatine Ganglion Block Study (NCT05707754) | Montefiore Medical Center | 2023-03-06 |
| Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers (NCT05792917) | Innovent Biologics (Suzhou) Co. Ltd. | 2023-03-06 |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation (NCT05737706) | Mirati Therapeutics Inc. | 2023-03-06 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects (NCT05758428) | Nuance Pharma (shanghai) Co., Ltd | 2023-03-06 |
| A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors (NCT04242147) | Kadmon, a Sanofi Company | 2023-03-06 |
| Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (NCT05531786) | National Cancer Institute (NCI) | 2023-03-06 |
| Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis (NCT05680233) | Oasis Pharmaceuticals, LLC | 2023-03-06 |
| A Trial of SHR-7367 in Subjects With Advanced Solid Tumors (NCT05740202) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-03-06 |
| PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers (NCT05723510) | HK inno.N Corporation | 2023-03-06 |
| Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults (NCT05894148) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2023-03-06 |
| Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC (NCT05956314) | Orvida Pharma (formerly Kamari Pharma) | 2023-03-06 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults (NCT06302374) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2023-03-04 |
| SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma. (NCT05293912) | Hangzhou Sumgen Biotech Co., Ltd. | 2023-03-03 |
| Different Treatment Modalities for Oral Lichen Plan (NCT06681090) | Al-Azhar University | 2023-03-03 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) (NCT05708950) | Kineta Inc. | 2023-03-03 |
| Evaluate Pharmacokinetics and Safety of Slow Release DHEA (NCT05623059) | Indiana University | 2023-03-03 |
| Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (NCT05322954) | University of Wisconsin, Madison | 2023-03-03 |
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (NCT05567185) | Janssen Pharmaceutical K.K. | 2023-03-03 |
| A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors. (NCT05735275) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-03-03 |
| A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene (NCT05469178) | BerGenBio ASA | 2023-03-03 |
| Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas (NCT05768919) | SignPath Pharma, Inc. | 2023-03-03 |
| A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies (NCT05753722) | Incendia Therapeutics | 2023-03-03 |
| A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. (NCT06298071) | Shanghai Institute Of Biological Products | 2023-03-03 |
| A Study of AK129 in Patients With Advanced Malignant Tumors (NCT05645276) | Akeso | 2023-03-02 |
| A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy (NCT05668403) | Shanghai Jiaolian Drug Research and Development Co., Ltd | 2023-03-02 |
| A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD) (NCT05551741) | Immunobrain Checkpoint | 2023-03-02 |
| A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors (NCT05911464) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2023-03-02 |
| Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing (NCT05547542) | Cerevel Therapeutics, LLC | 2023-03-02 |
| A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age (NCT05650333) | Pfizer | 2023-03-02 |
| A Single-dose Study of Octreotide Injection in Healthy Adult Subjects (NCT05761431) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-03-02 |
| A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer (NCT05775575) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-03-02 |
| Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) (NCT05698329) | AiViva BioPharma, Inc. | 2023-03-02 |
| Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) (NCT05905120) | Shanghai Mental Health Center | 2023-03-02 |
| Evaluation of Apraglutide on Gastric Emptying (NCT05995704) | VectivBio AG | 2023-03-02 |
| A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations (NCT05766709) | Novo Nordisk A/S | 2023-03-02 |
| This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults (NCT05386914) | University of Missouri-Columbia | 2023-03-02 |
| UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (NCT05775666) | Peking University | 2023-03-01 |
| Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke (NCT04818944) | University of Iowa | 2023-03-01 |
| Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis (NCT02903212) | Centre Hospitalier Universitaire de Besancon | 2023-03-01 |
| Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer (NCT05472506) | Ikena Oncology | 2023-03-01 |
| A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors (NCT06231550) | FindCure Biosciences (ZhongShan) Co., Ltd. | 2023-03-01 |
| CART-PSMA Cells for Advanced Prostate Cancer (NCT05656573) | Nova Therapeutics LLC | 2023-03-01 |
| Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain (NCT05588453) | Kari Kendra | 2023-03-01 |
| Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. (NCT05286320) | National Taiwan University Hospital | 2023-03-01 |
| A Study to Assess the Use of Methylone in the Treatment of PTSD (NCT05741710) | Transcend Therapeutics | 2023-03-01 |
| Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors (NCT05584709) | Sorrento Therapeutics, Inc. | 2023-03-01 |
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia (NCT06098014) | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 2023-03-01 |
| Carnosine for Peripheral Arterial Disease Patients (NCT05371145) | Shahid Baba | 2023-03-01 |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML (NCT05330377) | Ayman H Qasrawi | 2023-03-01 |
| Oxycodone in Combination With Parathoracic Nerve Block is Used for Postoperative Analgesia in Lung Cancer (NCT05742256) | Qianfoshan Hospital | 2023-03-01 |
| A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr (NCT05519670) | Institut Paoli-Calmettes | 2023-03-01 |
| Effect of Supplementation With Anthocyanins on Iron Metabolism in Female Swimmers (NCT06486623) | Poznan University of Physical Education | 2023-03-01 |
| First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma (NCT05607498) | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | 2023-03-01 |
| Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma (NCT05759312) | Fudan University | 2023-03-01 |
| Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants (NCT05782179) | Minervax ApS | 2023-03-01 |
| Metformin and Esomeprazole For Preterm Pre-eclampsia (NCT05232994) | Christiana Care Health Services | 2023-03-01 |
| Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms (NCT06307093) | R-Pharm | 2023-03-01 |
| Pharmacokinetics of VVN461 Ophthalmic Solution (NCT06906198) | VivaVision Biotech, Inc | 2023-03-01 |
| Oral Isotretinoin in Melasma a Randomized Controlled Trial (NCT06201624) | Zagazig University | 2023-03-01 |
| Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009) (NCT06843993) | Merck Sharp & Dohme LLC | 2023-03-01 |
| Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors (NCT05728541) | CSPC Ouyi Pharmaceutical Co., Ltd. | 2023-03-01 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (NCT05627245) | National Cancer Institute (NCI) | 2023-03-01 |
| EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (NCT04509726) | Xinqiao Hospital of Chongqing | 2023-03-01 |
| Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post Refractive Surgery and Associated With Blepharospasm (NCT05738629) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2023-03-01 |
| AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma (NCT05740891) | Zhejiang University | 2023-03-01 |
| Safety and Efficacy of DCB-BO1301 in Advanced Melanoma (NCT02994498) | Chung Mei Biopharma Co., Ltd | 2023-03-01 |
| Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients (NCT03932318) | Actinium Pharmaceuticals | 2023-03-01 |
| Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer (NCT05667298) | University of Manitoba | 2023-03-01 |
| Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir (NCT05731804) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2023-03-01 |
| Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma (NCT06321562) | EyeD Pharma | 2023-03-01 |
| Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma (NCT05675462) | Fudan University | 2023-03-01 |
| A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (NCT05589844) | Roswell Park Cancer Institute | 2023-03-01 |
| Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study (NCT06074757) | Kashiv BioSciences, LLC | 2023-03-01 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) (NCT05573555) | Pfizer | 2023-03-01 |
| Clinical Study of Meplazumab to Treat With Malaria (NCT04327310) | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | 2023-03-01 |
| Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients (NCT06740149) | Sun Yat-sen University | 2023-03-01 |